Trending...
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Martial Artists Invited to Push Their Limits at the 2025 JMAC Crucible in Ann Arbor
Varian Biopharmaceuticals is Developing a Proprietary atypical Protein Kinase C iota Inhibitor in Multiple Formulations for A Broad Range of Tumor Types
NAPLES, Fla. - Michimich -- Varian Biopharmaceuticals, Inc. ("VarianBio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, today announced its President and CEO, Jeffrey Davis, will be presenting at the Inflection Partners Fall Investment Conference entitled "Excellence in Execution."
The Inflection Partners Fall Conference will take place virtually on November 16-17, 2021, and Mr. Davis is scheduled to present at 2:40 pm ET on Tuesday, November 16, 2021. To register for the Inflection Partners conference, please visit: www.inflectionpartnersllc.com/fallconference
This event will feature more than 25 companies, ranging from disruptive seed stage startups to $1bn+ market cap public companies. This year's conference supports the Travis Manion Foundation (TSF), which strives to unite and strengthen communities by training, developing, and highlighting the role models that lead them. Travis Manion was an experienced and decorated Marine who was killed in action on April 29, 2007, in Iraq. The TSF develops programs, training opportunities, and events designed to empower veterans and families of the fallen while inspiring them to pass their values on to the next generation and the community at large. For more information, please visit travismanion.org.
More on Michimich.com
About Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. ("VarianBio") is private precision oncology company developing novel therapeutics for the treatment of cancer. Precision oncology, whereby physicians use DNA testing to look for genetic mutations of the unique tumors, holds the promise of more targeted treatment recommendations with therapies designed to fight specific tumor types. Varian Bio is developing a best-in-class high-potency, specific atypical protein kinase C iota ("aPKCi") inhibitor for the treatment of various tumor types in multiple formulations. Recent scientific publications have characterized aPKCi as a bonafide oncogene whose activity may play a fundamental role in the regulation of cancer-associated transcription factors including GLI-1 and K-RAS. Varian Bio's lead drug candidate, VAR-101, being developed in a topical formulation for the treatment of basal cell carcinoma. VAR-102, an oral formulation, is being developed for the treatment of a wide variety of solid tumors where studies have shown potent aPKCi inhibition would be impactful, including non-small cell lung cancer (NSCLC), pancreatic cancer and colorectal cancer. Additionally, Varian Bio is seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. For more information, please visit www.varianbio.com.
Forward-Looking Statements – Safe Harbor Statement
More on Michimich.com
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company's future plans, strategies and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek" or "project" or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and the expectations expressed in forward-looking statements may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, over many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Contacts:
Investors and Media
Jeffrey B. Davis
President & CEO
jdavis@varianbio.com
The Inflection Partners Fall Conference will take place virtually on November 16-17, 2021, and Mr. Davis is scheduled to present at 2:40 pm ET on Tuesday, November 16, 2021. To register for the Inflection Partners conference, please visit: www.inflectionpartnersllc.com/fallconference
This event will feature more than 25 companies, ranging from disruptive seed stage startups to $1bn+ market cap public companies. This year's conference supports the Travis Manion Foundation (TSF), which strives to unite and strengthen communities by training, developing, and highlighting the role models that lead them. Travis Manion was an experienced and decorated Marine who was killed in action on April 29, 2007, in Iraq. The TSF develops programs, training opportunities, and events designed to empower veterans and families of the fallen while inspiring them to pass their values on to the next generation and the community at large. For more information, please visit travismanion.org.
More on Michimich.com
- Be Part of the World's Largest Art Biennale | Moons, Castles, Trees | Copenhagen Chronotopes
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Rocket Companies to Announce Second Quarter 2025 Results on July 31, 2025
- Rent Like A Champion Acquires CollegeWeekends
About Varian Biopharmaceuticals, Inc.
Varian Biopharmaceuticals, Inc. ("VarianBio") is private precision oncology company developing novel therapeutics for the treatment of cancer. Precision oncology, whereby physicians use DNA testing to look for genetic mutations of the unique tumors, holds the promise of more targeted treatment recommendations with therapies designed to fight specific tumor types. Varian Bio is developing a best-in-class high-potency, specific atypical protein kinase C iota ("aPKCi") inhibitor for the treatment of various tumor types in multiple formulations. Recent scientific publications have characterized aPKCi as a bonafide oncogene whose activity may play a fundamental role in the regulation of cancer-associated transcription factors including GLI-1 and K-RAS. Varian Bio's lead drug candidate, VAR-101, being developed in a topical formulation for the treatment of basal cell carcinoma. VAR-102, an oral formulation, is being developed for the treatment of a wide variety of solid tumors where studies have shown potent aPKCi inhibition would be impactful, including non-small cell lung cancer (NSCLC), pancreatic cancer and colorectal cancer. Additionally, Varian Bio is seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. For more information, please visit www.varianbio.com.
Forward-Looking Statements – Safe Harbor Statement
More on Michimich.com
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- Unlocking PLM's Full Potential: CIMdata Reveals the Executive Support Imperative in Free Webinar
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company's future plans, strategies and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek" or "project" or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and the expectations expressed in forward-looking statements may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, over many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Contacts:
Investors and Media
Jeffrey B. Davis
President & CEO
jdavis@varianbio.com
Contact
media@varianbio.com
media@varianbio.com
Source: Varian Biopharmaceuticals, Inc.
Filed Under: Health
0 Comments
Latest on Michimich.com
- Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization
- "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
- RECOMMENDED CASH AND SHARE COMBINATION OF DOWLAIS GROUP PLC WITH AMERICAN AXLE & MANUFACTURING HOLDINGS, INC.
- The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- Roofman USA Shares the Pros and Cons of Summer vs. Fall Roof Replacements
- Wilderness Construction Shares Storage Solutions to Take You Kitchen Remodel to the Next Level
- The Bridge Chiropractic in Ann Arbor Offers Groundbreaking Approach to Knee Pain Relief
- Martial Artists Invited to Push Their Limits at the 2025 JMAC Crucible in Ann Arbor
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Michigan Personal Injury Lawyers, Matz Injury Law, Announces Over $10 Million Savings for Clients Through Reduced Fee Model
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas